Lenalidomide Sandoz 10 Mg Hard Capsules

Lenalidomide, the active ingredient in Lenalidomide Sandoz 10 mg hard capsules, is an immunomodulatory imide drug (IMiD) presented as a 10 mg oral capsule for prescription use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma in adult patients, typically within the European Union market.

GNH USA supplies Lenalidomide Sandoz 10 mg hard capsules as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, transplant units and pharmacies worldwide through regulated channels, and ensuring compliance with local regulations.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

Multiple Myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease. Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia in patients with del(5q) cytogenetic abnormality. Mantle Cell Lymphoma: contributes to disease control in relapsed or refractory cases when combined with other therapies.

Lenalidomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Rash: mild skin eruptions or itching.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury.

When prescribing Lenalidomide, several precautions should be observed to minimize risks.

Pregnancy risk: avoid use in pregnant women; effective contraception required for both male and female patients of reproductive potential. Thrombosis prophylaxis: assess need for anticoagulation in patients with additional risk factors. Renal impairment: adjust monitoring and consider dose modification in patients with reduced kidney function. Hepatic function: monitor liver enzymes regularly, especially in patients with pre‑existing liver disease. Infection monitoring: watch for signs of infection due to neutropenia or immunosuppression. Store at ambient temperature: keep capsules below 25 °C in the original container, protect from moisture and direct light.

Lenalidomide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with lenalidomide‑induced thrombocytopenia. - Immunosuppressants: heightened risk of infection.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors: may increase plasma levels of lenalidomide. - NSAIDs: additive risk of renal impairment. - Vaccines: live attenuated vaccines may be less effective; avoid during therapy.